Allogene Therapeutics, Inc.ALLONASDAQ
LOADING
|||
ALLO Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +24.78% | +25.09% | +27.33% | +15.21% | +6.14% |
| Weighted Average Shares Diluted Growth | +24.78% | +25.09% | +27.33% | +15.21% | +6.14% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +0.00% | -100.00% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -17.30% | -14.64% | -13.37% | -27.25% | -25.35% |
| Book Value per Share Growth | -36.26% | -34.11% | -34.40% | -41.93% | -35.94% |
| Debt Growth | -11.94% | -4.59% | -15.18% | -15.89% | +0.01% |
| R&D Expense Growth | -2.75% | -17.73% | -3.94% | -20.25% | -30.30% |
| SG&A Expenses Growth | -4.15% | -9.90% | -13.18% | -11.23% | -15.89% |
1 / 4